Case studies

  • Oncology drug development plan Series A

    DIAMANTE helped an EU biotech build a validated oncology development plan, timeline, and budget to support Series A fundraising and execution.

    More about this case study

    The CEO of an EU-based, pre-clinical-stage biotech company asked DIAMANTE to work with the team to develop the preclinical and clinical development plan for an oncology drug candidate. At the time of engagement, the program had a clinical candidate, and the CEO was seeking expert development input to develop a Series A plan including TPP, plan for IND-enabling studies, First-in-human clinical study and clinical POC study up to the targeted approval indications.  

    DIAMANTE challenged and solidified the existing plans and, in cooperation with the team, prepared a detailed timeline and budget plan for Series A.  

    This enabled the client to have a solidly prepared plan, cross-validated by drug development experts to support their fundraising activities for Series A and allow for immediate and cost/time efficient target directed execution of plans.

  • CNS drug development at Seed stage

    DIAMANTE supported a European biotech in shaping its Alzheimer’s drug strategy, from discovery through early clinical planning, enabling a strong foundation for Series A fundraising.

    More about this case study

    The investor of a European early-stage biotech company developing a first-in-class oral therapy for Alzheimer’s disease engaged DIAMANTE to support the validation and execution of the discovery and preclinical development strategy in preparation for Series A financing. 

    DIAMANTE worked closely with the virtual project team to establish and continuously refine an integrated discovery plan. This plan covered in silico modelling, medicinal chemistry, and in vitro and in vivo pharmacology, with the goal of identifying a lead compound. Together with the team, DIAMANTE identified, selected, and managed a network of specialized CRO partners and external experts.  

    Further, based on the optimized scientific narrative, target product profile, and biomarker strategy, DIAMANTE designed the first-in-human development path. This included detailed timelines and resource estimates for all required IND-enabling studies.  

    This comprehensive support enabled the client’s Series A fundraising efforts and formed the core of an NIH grant application. 

  • Oncology Clinical candidate selection and Series A

    DIAMANTE supported a Swiss biotech in advancing its oncology program from lead optimization to clinical candidate selection and Series A planning.

    More about this case study

    A Swiss-based biotech founded out of a university engaged with DIAMANTE via their seed investor. DIAMANTE provided fractional management support to the company to lead their small molecule oncology program from lead identification/optimization to successful clinical candidate selection.  

    Specifically, this involved leadership of a virtual drug development team consisting of university personnel, CROs, and consultants. To guide the drug discovery efforts a screening funnel and TPP were established to allow a targeted selection of best compounds with all critical development properties (i.e. potency, efficacy, selectivity, ADME / physical & chemical properties, PK, tox profile, chemistry, and IP).

    In parallel, DIAMANTE coordinated the preparation of the preclinical and clinical development plan for Series A engaging with CROs, Clinical experts and providing drug development expertise.